RxDoctor Payments DataLook up a doctor →

Alfonso Bello, MD

Rheumatology · Glenview, ILNPI 1942252697

Payments from drug & device makers

$641,792in general payments, 2019–2025

Across 2,331 payments — averaging $275.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$196K
  • Amgen$102K
  • Novartis$90K
  • Mallinckrodt Hospital Products Inc.$86K
  • ANI Pharmaceuticals, Inc.$45K
  • Bristol Myers Squibb$41K
  • plus $83K from 35 others
$1,700in research payments, 2019–2025

Across 1 payment — averaging $1700.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$2K

What the payments were for

  • Consulting fees$51,8438%
  • Speaking & faculty fees$488,50280%
  • Travel & lodging$32,6345%
  • Food & beverage$37,5136%
  • Education$5140%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$641,792 in reported general payments places this provider in the 95th percentile of 287 rheumatology providers in Illinois.

See all rheumatology providers in Illinois

Medicare billing

Part B allowed, 2024
$2,505,921
Medicare patients
694
Services billed
196,614

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CortrophinCorticotropin19$1,249,270
RinvoqUpadacitinib126$1,137,143
Enbrel SureclickEtanercept41$317,731
Humira(Cf) PenAdalimumab31$316,850
OtezlaApremilast17$79,402
BenlystaBelimumab14$75,481
TymlosAbaloparatide20$58,860
Nucynta ErTapentadol Hcl13$30,619
OxycontinOxycodone Hcl22$17,150
Hydroxychloroquine Sulfate434$11,222
Leflunomide203$10,484
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen313$10,321
MethotrexateMethotrexate Sodium392$9,235
Xtampza ErOxycodone Myristate12$8,736
Fentanyl75$6,558

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$196,051$1,137,143126 claims
AmgenOtezla$101,740$79,40217 claims
GSKBenlysta$2,453$75,48114 claims
Radius Health, Inc.Tymlos$242$58,86020 claims
Collegium Pharmaceutical, Inc.Nucynta Er, Xtampza Er$496$39,35525 claims
Hikma Pharmaceuticals USABuprenorphine$233$6,19422 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 287 rheumatology providers in Illinois.

Other rheumatology in Glenview

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →